Measurement of Residual Disease After Neoadjuvant Chemotherapy-Reference-Cited by-同舟云学术

Measurement of Residual Disease After Neoadjuvant Chemotherapy

Published:2008-06-20 Issue:18 Volume:26 Page:3094-3094
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Abrial Catherine¹,Thivat Emilie¹,Tacca Olivier¹,Durando Xavier²,Mouret-Reynier Marie-Ange²,Gimbergues Pierre²,Penault-Llorca Frédérique²,Chollet Philippe³

Affiliation:

1. Centre Jean Perrin and INSERM, Clermont-Ferrand, France

2. Centre Jean Perrin and INSERM; and Faculté de Médecine, Université d'Auvergne, Clermont-Ferrand, France

3. Centre Jean Perrin and INSERM; Faculté de Médecine, Université d'Auvergne; and Centre d'Investigation Clinique, Clermont-Ferrand, France

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2008.16.7817

Reference6 articles.

1. Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy

2. American Joint Committee on Cancer Tumor–Node–Metastasis Stage After Neoadjuvant Chemotherapy and Breast Cancer Outcome

3. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response

4. Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer?

5. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated tumor genomic and immune microenvironment analysis identifies predictive biomarkers associated with the efficacy of neoadjuvant therapy for triple‐negative breast cancer;Cancer Medicine;2022-10-21

2. Predictive biomarkers for personalized medicine in breast cancer;Cancer Letters;2022-10

3. Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers;npj Breast Cancer;2022-05-10

4. Cancer cell segmentation for cellularity prediction via a weakly labeled/strongly labeled hybrid convolutional neural network;Medical Imaging 2022: Digital and Computational Pathology;2022-04-04

Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer

;Drug Design, Development and Therapy;2020-06